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Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder 
induces the expression of immune and cell proliferation related genes
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Bladder cancer is a common malignancy. Numerous 
studies have demonstrated that increased expression of 
cyclooxygenase enzyme 2 (COX-2), which catalyzes the 
synthesis of prostaglandins (PGs), is associated with the 
development and progression of certain type of cancers, 
including bladder cancer. However, the exact role of 
COX-2/PGs play in bladder carcinogenesis remains 
unknown. We have recently developed a transgenic 
mouse model which overexpresses COX-2 under the 
control of a bovine keratin 5 (BK5) promoter. The 
BK5.COX2 mice develop high incidence of bladder 
transitional cell hyperplasia (TCH) and a relative lower 
incidence of bladder papilloma. We then conducted a 
micorarray gene analysis to determine the effects of 
COX-2 overexpression on the regulation of gene 
expression profile in bladder carcinogenesis. Analysis of 
gene array data by t-test (p<0.05) revealed 70 of the 
upregulated genes and 60 of the downregulated genes 
had expression changed by 2-fold or more in transgenic 
compared to wild-type bladders. Gene set analysis using 
Expression Analysis Systematic Explorer software 
revealed that genes associated with Immune/Stress 
Response and Cell Cycle/Proliferation biologic processes 
were significantly overrepresented in the top 100 
upregulated genes. Relevant downregulated genes 
included three TGF beta related genes (Tgfb2, Tgfb3, 
Tgfbi), and the anti-angiogenic gene thrombospondin 2 
(Thbs2). We further demonstrated that the growth factor, 
epiregulin, is the most highly induced gene among the 
genes validated by real-time PCR. The results of gene 
expression analysis indicate that the initial response of 
the mouse bladder to elevated COX-2 expression 
includes mounting an inflammatory response and 
inducing cell proliferation. Future studies will focus on 
determining the role of the immune response in 
promoting or inhibiting the hyperplastic response of the 
bladder transitional epithelium. The role of epiregulin and 
the downstream signaling molecules in bladder 
carcinogenesis will also be determined. This study was 
supported by grants CA091865 and CA100140 from the 
National Cancer Institute.
ABSTRACT
INTRODUCTION
METHODS
BK5.COX2 MODEL
To determine the effect of COX-2 
overexpression on the gene 
expression profile in bladder 
epithelium.
To explore potential mechanisms by 
which COX-2 can influence urinary 
bladder carcinogenesis.
RESULTS
Ki67 staining is increased in BK5.COX2 mice
Materials. Polyclonal murine COX-1, COX-2 antibodies and PGE2 EIA kit were from 
Cayman Chemical (Ann Arbor, MI). anti-rabbit HRP-linked IgG and HRP-conjugated anti-
biotin antibody were from Cell signaling (Beverly, MA). Polyclonal beta-actin antibody was 
obtained from Abcam (Cambridge, MA). TRIzol reagent was purchased from Invitrogen
(Carisbad, CA). RNeasy Mini-RNA extraction kit was purchased from Qiagen (Valencia, 
CA). The iScript cDNA synthesis kit was purchased from Bio-Rad (Hercules, CA). All 
primers (COX-1, COX-2, epiregulin, IGF-1, IGFBP6, TGFBi, TGFB2 TGFB3 and GAPDH) 
were purchased as Taqman® Gene Expression Assay kits from Applied Biosystems (Foster 
City, CA) as was the Taqman® Universal PCR Mastermix. 
Animal Maintenance. Wild-type FVB mice and BK5.COX2 transgenic mice (FVB 
background) were kept in the University Laboratory Animal Resources (ULAR) facility of the 
Ohio State University (OSU) under an artificial day/night rhythm and fed chow diet and water 
ad libitum. Wild-type Female FVB mice were crossed with male BK5.COX2 mice to get the 
litters. Only female wild-type and transgenic mice were used for these studies.
Real-time PCR. Total RNA from age matched wild-type and BK5.COX2 mice was isolated 
from tissue using TRIzol reagent and further purified using RNeasy columns. RNA from 
three pooled wild-type mouse bladders was used as a calibration sample. Total RNA were 
subsequently analyzed with the Agilent Bioanalyzer 2100 system at the OSU CCC real-time 
PCR shared facility. Total RNA (1µg) was reverse transcribed with iScript cDNA synthesis 
kit . Real-time PCR was performed on a 1:10 dilution of the cDNA  using Taqman gene 
expression primers and ABI mastermix according to the manufacturer’s instructions on an 
iCycler IQ Real-Time PCR detection system (Bio-Rad). GAPDH was used as the reference 
gene for all samples. 
Affymetrix microarray and EASE Analysis. Bladder tissues were excised from 10 wk 
old wild-type and BK5. COX-2 transgenic mice (5 mice/group). Total RNA were extracted by 
TRIzol reagent and then purified by RNeasy kit. The Affymetrix microchip analysis was 
performed by the Microarray Core Facility at the Columbus Children’s Hospital Medical 
Center. Ten Mouse 430 GeneChips (Affymetrix Inc., Santa Clara, CA) were used; one chip 
for each sample. Affymetrix MicroArray Suite was used to scan and quantitate the 
genechips. Intensity data were collected from each chip and hybridization data were 
sequentially subjected to normalization, transformation, filtering, and functional 
classification. Differentially expressed genes in BK5.COX2 mice versus wild-type mice were 
identified by log2-differences and by t-test. The results were further analyzed using 
Expression Analysis Systematic Explorer (EASE; NIH) with the Benjamini false discovery 
rate correction for multiple testing. 
Tissue Preparation and Histological Analysis. Urinary bladders were excised and 
fixed in 10% Formalin. The fixed bladders were then bisected longitudinally through the 
urethral opening and positioned with the cut faces oriented in the same direction for paraffin 
embedding. Four-micron sections were stained with hematoxylin and eosin (H&E) by
standard protocols. Immunohistochemical staining was carried out using modified ABC 
techniques. Primary antibody dilution for COX-2 was 1:2000 overnight at 4ºC. Species 
appropriate biotinylated secondary antibodies were used at 1:200 for two hours at RT 
followed by ABC-HRP or SA-HRP treatment for 30 minutes at RT. Slides were developed 
with DAB for approximately five minutes. Mouse Ki-67 staining was performed by the 
histopathology core at OSU. 
Immunoblot Analysis. Immunoblot analysis of COX-2, COX-1 and beta-actin were 
carried out according to the antibody manufacturer’s instructions. Cell lysates from mouse 
vas deferens was used as positive control. 
PGE2 Measurement. PGE2 concentrations in transgenic and wild-type mice were 
determined by PGE2 EIA kit according to manufacturer's instruction from Cayman Chem. 
Statistical Analysis. All data were analyzed by SPSS software. Values are means + SD. 
Statistical significance (p <0.05) was determined by t-test. 
COX-2 overexpression induces the regulation 
of genes involved in immune/stress, 
antiangiogenic, proliferation/cell cycle and  
extracellular matrix remodeling events as 
initiating responses.
The growth factor, epiregulin, is the most 
significantly upregulated gene as validated by 
qRT-PCR.
The expression of epiregulin and the TGF-
beta family were consistently deregulated with 
the progression of urinary mouse bladder 
carcinogenesis.
BK5. COX2 may serve as a mouse model of 
human bladder carcinogenesis.
Biomarkers of COX-2 overexpression may be 
useful in future translational chemoprevention 
studies focusing on bladder cancer.
OBJECTIVES
Murine COX-2 cDNA SV40-poly A -3’5’- Bovine Keratin 5 Promoter
FVB background 
COX-2 is driven by bovine keratin-5 
promoter expressed in basal cells
Expressed in epidermis, bladder,          
prostate, mammary gland and pancreas
Hairless - defect in follicle development
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Regulation of gene expression profile by COX-2 overexpression in the BK5.COX2 mouse bladder at an early stage of carcinogenesis
COX-2 and COX-1 expression in the urinary bladder of BK5.COX2 transgenic mice
Figure 3. Affimatrix Microarray analysis of gene regulation in 10 wk old BK5.COX2 mice (n=5) compared to the wild-types (n=5). A. Upregulated genes; B. Downregulated genes.  Analysis of gene array data by t-test (p<0.05) revealed that 
2270 genes were upregulated and 1740 genes were downregulated in transgenic compared to wild-type mice. Seventy upregulated genes and sixty downregulated genes had expression changed by 2-fold or more (bold text) in transgenic compared 
to wild-type bladders. Gene set analysis of the array data using Expression Analysis Systematic Explorer (EASE; NIH) software determined that genes associated with Immune/Stress Response, Cell Cycle/Proliferation process, and Extracellular
matrix remodeling were upregulated (A) (EASE<0.05; Benjamini<1.0); relevant downregulated genes include TGF-beta related genes (Tgfb2, Tgfb3, Tgfbi), and the anti-angiogenic gene thrombospondin 2 (Thbs2) (Panel B, red text). 
Determine the presence and level of all the 
prostaglandins and their respective receptors.
Determine the role of epiregulin and the 
downstream signaling molecules in bladder 
carcinogenesis. 
Examine the interaction between COX-2 and 
TGF-beta signaling pathways in bladder 
carcinogenesis. 
Explore the role of the immune response in 
regulating the hyperplastic response of the   
bladder transitional epithelium.
CONCLUSIONS
Bladder cancer represents an important heath concern.  
The identification of new molecular targets for bladder 
cancer prevention and therapy is a potential means to 
reduce the development and progression of this disease. 
Numerous studies have demonstrated that COX-2 is 
overexpressed in TCC of human urinary bladder [1-4]. The 
degree of COX-2 expression is significantly correlated with 
the tumor grade and depth of invasion (T stage) of TCC [5-7]. 
Increased COX-2 expression has also been reported in rat 
and canine models of bladder cancer [8, 9]. A case-control 
study involving 1514 incident bladder cancer cases and an 
equal number of controls indicated that NSAID (COX 
inhibitors) users have an almost 20% decreased risk for 
urinary bladder cancer [10]. A number of studies have 
demonstrated that NSAIDs are able to inhibit the growth of 
bladder cancer cells in vitro [11-14]. In addition, COX 
inhibitors also induced remission of chemically induced 
bladder tumors in rodents [15-16], naturally occurring invasive 
TCC in dogs [17-18], and bladder carcinoma in an orthotopic
mouse model [19]. We have recently demonstrated that 
forced expression of COX-2, under the control of a keratin 5 
(K5) promoter, is sufficient to cause urinary bladder 
transitional cell hyperplasia (TCH), which progresses to 
TCC in a small percentage of transgenic mice [20]. The level 
of prostaglandin E2 (PGE2), the major product of COX-2, 
was significantly increased in the bladder of BK5.COX2 
mice. PGE2 has also been reported to be elevated in 
patients with bladder cancer [4, 21]. 
The above studies suggest that there is a strong 
association between COX-2, prostaglandin synthesis and 
the development and progression of urinary bladder cancer. 
However, the exact role and mechanisms of COX-2 
overexpression during bladder carcinogenesis have not 
been well defined. To determine the molecular events 
elicited by  COX-2 overexpression during the early stage of 
bladder carcinogenesis (before the onset of substantial 
TCH), we conducted DNA microarray expression analysis 
on urinary bladders from 10 wk old wild-type  and 
BK5.COX2 transgenic mice. Our study is innovative in that 
we were able to study gene expression changes that were 
due solely to the overexpression of COX-2 in the bladder 
tissue of a novel transgenic mouse model. This model may 
serve as a potentially useful model to study the etiology and 
prevention of human urinary bladder cancer. 
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Figure 1. Confirmation of COX-2 transgene expression and PGE2 production in BK5.COX2 transgenic mice. A. H&E 
staining and IHC staining with anti-COX-2. No COX-2 expression is observed in wild-type epithelial cells, whereas intense 
staining of COX-2 is present in the epithelial cells of transgenic bladders. B. qRT-PCR analysis. GAPDH was used as the 
reference gene. Results are represented as average expression relative to calibration sample (Error bars indicate the standard 
deviation, n=5, p<0.05). C. Immunoblotting analysis. 1-2: Wild-type; 3-4: Transgenic; (+): positive control. D. Elevated PGE2
production in transgenic bladders compared to wild-type mice (Error bars indicate the standard deviation, n=4). 
Figure 4. qRT-PCR validation of six genes of interest that were significantly regulated in 10 wk old BK5.COX2 transgenic 
mice by Gene Array analysis.  Note that epiregulin is the most significantly upregulated gene (increased in BK5.COX2 by 
3.7 fold, p<0.01). GAPDH was used as the reference gene. Results are represented as average expression relative to a 
calibration sample (Error bars indicate the standard deviation, n=5). As denoted by color, red: significantly upregulated 
genes, blue: significantly downregulated genes, grey: no significance (p<0.05). 
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Figure 2. Histopathology of BK5.COX2 transgenic mouse bladder. A. Bladders from 10 wk old wild-type (a-c) and 
BK5.COX2 (d-f) mice.  Note the thin epithelium (black arrow) in wild-type bladders in panel a, b and c.  Note the simple 
TCH denoted by diffuse papillary extensions into the bladder lumen (d to f)) and thickened hyperplastic epithelium 
(black arrow in panel d and e), and increased hyperchromatic nuclei (f) and apoptotic cells (blue arrow in f). B. Bladders 
from older (20-30 wks) BK5.COX2 mice. Note the thickened lamina propria (* in a) and increased TCH, very often, the 
nodular hyperplasia (blue arrow in a) that characterized by the downward proliferation into the lamina propria and nests 
of epithelial cells (a-b). Note the nests of darkly strained inflammatory cells in panel a (black arrow) and panel c at 
higher magnification. Multifocal transitional cell papilloma and possible carcinoma in situ (d). Transitional cell  papilloma
(e-f), given more time, may progress to carcinoma.
Figure 6. IHC staining of the proliferation marker Ki67 in 10 wk old wild-
type and BK5.COX2 transgenic urinary bladders. Note that the number of 
epithelial cells positive for Ki67 is significantly increased in bladders from 
transgenic mice (d-f) . Whereas, very few cells were stained positive for 
Ki67 in the wild-type bladder epithelial cells (a-c, arrow in panel c at 400x).  
Figure 5. Expression of the six validated genes in 30 wk old BK5.COX2 transgenic mice and age matched wild-type 
mice by qRT-PCR analysis. Note that epiregulin is again the most significantly upregulated gene in 30 wk old animals 
(increased in BK5.COX2 by 5.3 fold, p<0.01). GAPDH was used as the reference gene. Results are represented as 
average expression relative to a calibration sample (Error bars indicate the standard deviation, n=5). As denoted by color, 
red: significantly upregulated genes, blue: significantly downregulated genes, grey: no significant change (p<0.05).
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